QPS Holdings, a full-service CRO, has opened a new in vitro dermatology and transdermal research laboratory in Fargo, N.D. This new physical extension of QPS’ dermal and transdermal research services portfolio will further strengthen QPS’ ability to assist clients in quickly moving their dermal and transdermal products from preclinical evaluations through to late stage clinical development.
“With QPS’ increasing early phase clinical presence in topical and transdermal pharmacokinetics and bioequivalence, this is a logical step in the evolution of our dermal and transdermal research services division,” said Ben Chien, Ph.D., QPS president and CEO.
The laboratory will be directed by Paul A. Lehman, MSc, vice president and head of QPS dermal and transdermal research services. This research facility is backed by 36 years of topical pharmacokinetics experience with the Franz Diffusion Cell. This model and associated methodologies support dermal drug development testing in the preclinical, clinical and post-approval phases, including the in vitro rate-of-release assay based on the FDA SUPAC-SS Guidance.